Blinatumomab Approval Expanded Based on MRD.
The FDA recently expanded the approval of blinatumomab using minimal residual disease (MRD) as a regulatory endpoint, which could signal more such approvals to come. The drug can now be used to treat adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission and have MRD.